The world’s most comprehensive and practical reference source about drugs and medicines

Unrivalled in its field, Martindale provides practical, evidence-based, global guidance, allowing you to quickly understand the characteristics of drugs and other pharmaceutical substances and their clinical uses.

SubscribeContent Updates
Features and Benefits icon

Global source of information: International, multi-lingual coverage, including synonyms, drug and chemical identifiers, chemical formulae, structures and pharmacopeial standards

Features and Benefits icon

Breadth of content: Expertly curated data on over 248,000 medicines provides an unparalleled, consolidated database of preparations

Features and Benefits icon

Range of drugs: Provides concise and accurate information on herbals, diagnostic agents, radiopharmaceuticals, pharmaceutical excipients, toxins and poisons

Features and Benefits icon

Reviewed and updated every 3 months by expert teams

7,500 +

drugs

54,000

references

40

regions and countries covered

6 +

languages

Publication Updates

14 Sep
Martindale logo
Martindale September 2018 update

This update contains 8 new monographs and 7 existing monographs have been updated. Preparations have been updated for 6 countries.

New Monographs:

  • Abemaciclib: is a cyclin-dependent kinases 4 and 6 inhibitor used in the treatment of advanced or metastatic breast cancer.
  • Axicabtagene ciloleucel: is an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy that is used for the treatment of relapsed or refractory large B-cell lymphoma.
  • Burosumab: is a monoclonal antibody that inhibits fibroblast growth factor 23 that is used for the treatment of X-linked hypophosphataemia.
  • Erenumab: is a human monoclonal antibody that inhibits the activity of calcitonin gene-related peptide and is used for the prevention of migraine.
  • Ibalizumab: is a post-attachment HIV-1 inhibitor used in the treatment of multidrug-resistant HIV infection.
  • Lutetium-177: is a radionuclide that is used to label medicinal products.
  • Lutetium (177Lu) oxodotreotide: is a radioconjugate that is used for the treatment of gastroenteropancreatic neuroendocrine tumours.
  • Tisagenlecleucel: is an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy that is used for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukaemia in patients up to 25 years of age.

Notable revisions:

  • Dalbavancin: can be used in a single-dose regimen for the treatment of acute bacterial skin and skin structure infections.
  • Evolocumab: also licensed to reduce cardiovascular risk in established cardiovascular disease.
    Tocilizumab: also licensed for giant cell arteritis and for chimeric antigen receptor (CAR) T-cell induced cytokine release syndrome.

Proprietary Preparations and Manufacturers updated for the following countries and regions:

Austria, China, South Africa, UAE, UK and USA. († Countries updated on an ongoing basis)  

11 Jun
Martindale logo
Martindale June 2018 update

This update contains 11 new monographs and 28 existing monographs have been updated. Preparations have been updated for 5 countries. 

New Monographs:

  • Bictegravir: is an HIV-integrase inhibitor used in the treatment of HIV infection. 
  • Cerliponase alfa: is a recombinant enzyme used to slow the loss of motor function and language skills in symptomatic patients with late-infantile neuronal ceroid lipofuscinosis type 2. 
  • Ertugliflozin: is a sodium-glucose co-transporter 2 inhibitor that is used for the treatment of type 2 diabetes mellitus. 
  • Gusekumab: is an antibody that targets interleukin-23 and is used for the treatment of plaque psoriasis. 
  • Letermovir: is a CMV DNA terminase complex inhibitor that is used for the prophylaxis of CMV infection and disease in adult CMV-seropositive recipients of an allogeneic haematopoietic stem cell transplant. 
  • Macimorelin: is a growth hormone stimulant used orally for the diagnosis of adult growth hormone deficiency. 
  • Migalastat: is a stabiliser of the alpha galactosidase A enzyme that is used orally in the treatment of Fabry disease. 
  • Naldemedine: is a peripherally-acting opioid antagonist used for the treatment of opioid-induced constipation in patients with chronic, non-cancer pain. 
  • Ozenoxacin: is a quinolone antibacterial applied topically in the treatment of impetigo. 
  • Semaglutide: is a glucagon-like peptide 1 receptor agonist used in the treatment of type 2 diabetes mellitus. 
  • Voretigene neparvovec: is a gene therapy product used for treating biallelic RPE65 mutation-associated retinal dystrophy. 

Notable revisions:

  • Asfotase alfa: also licensed for paediatric-onset hypophosphatasia. Adverse effects and precautions has been updated. 
  • Canagliflozin: abstract on risk of amputation added. 
  • Ceftriaxone Sodium: uses and administration has been updated. 
  • Ceritinib: uses extended to include first-line treatment of metastatic non-small cell lung cancer. 
  • Desmopressin:  new abstract on administration added. Uses and administration has been updated. 
  • Eculizumab: also licensed for use in myasthenia gravis. 
  • Empagliflozin: also licensed to reduce the risk of cardiovascular death in patients with type 2 diabetes mellitus. 
  • Interferon Alfa: also licensed for the treatment of hepatitis B in children. Adverse effects have been updated.  
  • Metformin: diabetes mellitus abstract has been updated with information on use in the prevention of type 2 diabetes mellitus. 
  • Methylthioninium Chloride: new record on incompatibility added and administration in children abstract has been updated. 
  • Ocrelizumab: also licensed for the treatment of relapsing and primary progressive multiple sclerosis. 
  • Ulipristal acetate: use for treating uterine fibroids restricted following reports of serious liver injury. 

Updated names, synonyms and codes; official standards; official preparation: Ph Eur 9.3 and USP40/USNF35 Suppl 1 and 2. 

Proprietary Preparations and Manufacturers updated for the following countries and regions:  India, Philippines, UK†, USA†, Venezuela. († Countries updated on an ongoing basis) 

13 Mar
Martindale logo
Martindale March 2018 update

This update contains 3 new monographs and 5 existing monographs have been updated. Preparations have been updated for 5 countries.

New monographs:

  • Acalabrutinib: is an inhibitor of Bruton’s tyrosine kinase used in mantle cell lymphoma.
  • Benralizumab: is an IL-5-alpha receptor antibody used as add-on maintenance treatment in severe eosinophilic asthma.
  • Netarsudil and Netarsudil Mesilate: is a Rho-kinase inhibitor used in the treatment of glaucoma and ocular hypertension.

Notable revisions:

  • Aliskiren Fumarate: also licensed for use in children. Interactions, reviews, and heart failure records have been updated.
  • Metformin Hydrochloride: licence extended for prevention of type 2 diabetes in high-risk patients. Administration in renal impairment abstract has been updated.
  • Sevelamer: can be used in children from 6 years of age.
  • Topiramate: uses and administration, adverse effects, and precautions records have been updated.
  • Tranexamic Acid: uses and administration updated, haemorrhagic disorders abstract has been updated.

Updated names, synonyms and codes; official standards; official preparations: Ph Eur 9.1, Ph Eur 9.2

Proprietary Preparations and Manufacturers updated for the following countries and regions: Argentina, Australia, Indonesia, UK†, USA†. († Countries updated on an ongoing basis)

12 Dec
Martindale logo
Martindale December 2017 update

This update contains 9 new monographs and 7 existing monographs have been updated. Preparations have been updated for 5 countries.

New monographs:

  • Cenegermin: is a recombinant human nerve growth factor that is used topically for the treatment of moderate or severe neurotrophic keratitis.
  • Copanlisib and Copanlisib Hydrochloride: is a phosphoinositide-3 kinase (PI3K) inhibitor that is licensed for the treatment of relapsed follicular lymphoma.
  • Enasidenib and Enasidenib Mesilate: is an inhibitor of isocitrate dehydrogenase-2 (IDH2) approved for the treatment of relapsed or refractory acute myeloid leukaemia with an IDH2 mutation.
  • Evogliptin: is a dipeptidylpeptidase-4 (DPP-4) inhibitor used in the management of type 2 diabetes mellitus.
  • Glecaprevir: is a NS3/4A protease inhibitor that is approved for the treatment of hepatitis C.
  • Niraparib and Niraparib Tosilate: is a PARP inhibitor that is licensed for the treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
  • Pibrentasvir: is a NS5A inhibitor that is used for the treatment of hepatitis C.
  • Sarilumab: is a human monoclonal antibody that targets the interleukin-6 receptor and is licensed for the treatment of moderate to severe active rheumatoid arthritis.
  • Voxilaprevir: is a NS3/4A protease inhibitor that is used for the treatment of hepatitis C.

Notable revisions:

  • Bicalutamide: adverse effects and precautions updated. Unlicensed dose for metastatic prostate cancer added. References updated.
  • Cladribine: an oral formulation is launched for the treatment of highly active relapsing multiple sclerosis.
  • Eribulin: is licensed for the treatment of liposarcoma.
  • Febuxostat: is licensed for the prevention and treatment of hyperuricaemia in patients undergoing chemotherapy for haematologic malignancies at intermediate to high risk of tumour lysis syndrome.
  • Ibrutinib: is licensed for use in marginal zone lymphoma and chronic graft-versus-host disease.
  • Ketamine Hydrochloride: use in obstetrics added. Pain and psychiatric disorders abstracts have been updated.
  • Palbociclib: is licensed for use with fulvestrant for endocrine-receptor positive, HER2-negative advanced or metastatic breast cancer that has progressed following prior endocrine therapy.

Updated names, synonyms and codes; official standards; official preparations: BP 2017

Proprietary Preparations and Manufacturers updated for the following countries and regions: Brazil, Greece, Malaysia, UK†, USA†. († Countries updated on an ongoing basis)

13 Sep
Martindale logo
Martindale September 2017 update

This update contains 10 new monographs and 12 existing monographs have been updated. Preparations have been updated for 5 countries.

New monographs:

  • Abaloparatide: is an analogue of human parathyroid hormone related peptide, given subcutaneously in the treatment of postmenopausal osteoporosis.
  • Baricitinib: is a Janus kinase inhibitor that is used orally for treating rheumatoid arthritis.
  • Brigatinib: is a tyrosine kinase inhibitor, used in the treatment of patients with metastatic non-small cell lung cancer that is ALK-positive and who have progressed on, or who are intolerant of, crizotinib.
  • Delafloxacin and Delafloxacin Meglumine: is a fluoroquinolone antibacterial that is used for the treatment of acute skin and skin structure infections caused by susceptible bacteria.
  • Deutetrabenazine: is a VMAT2 inhibitor, used for the management of tardive dyskinesia.
  • Durvalumab: is a monoclonal antibody now licensed in the USA for urothelial carcinoma.
  • Follitropin Delta: is a recombinant human follicle-stimulating hormone used in the treatment of female infertility as part of assisted reproductive technologies.
  • Ribociclib and Ribociclib Succinate: is an inhibitor of cyclin-dependent kinases 4 & 6, given with an aromatase inhibitor for advanced breast cancer in postmenopausal women.
  • Rucaparib: is now licensed in USA for advanced ovarian cancer.
  • Valbenazine: is a VMAT2 inhibitor, used for the treatment of Huntington’s chorea.

Notable revisions:

  • Brentuximab Vedotin: adverse effects and indications updated. New abstracts for administration in renal or hepatic impairment created.
  • Canakinumab: new indications and doses added for Still’s disease and periodic fever syndromes.
  • Ceftaroline Fosamil Acetate: doses for use in children (including those in renal impairment) updated.
  • Daclizumab: uses and adverse effects and precautions updated.
  • Dolutegravir: use in children from 6 years of age for the treatment of HIV-1 infection approved.
  • Eluxadoline: use in patients without a gallbladder contra-indicated.
  • Etoricoxib: doses for rheumatoid arthritis and ankylosing spondylitis updated.
  • Prasterone: use for the treatment of dyspareunia now licensed.
  • Sebelipase alfa: monograph expanded.
  • Tenofovir: tenofovir alafenamide fumarate is now also licensed for the treatment of chronic hepatitis B infection.
  • Triptorelin: use as adjuvant treatment of breast cancer in premenopausal women added.
  • Ustekinumab: uses extended to include the treatment of moderate to severe Crohn’s disease.

Updated names, synonyms and codes; official standards; official preparations: USP 40/USNF 35 Suppl 1.

Proprietary Preparations and Manufacturers updated for the following countries and regions: France, Hong Kong, India, UK, USA. ( Countries updated on an ongoing basis)